Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rex Fang & Innovation Equity Premium Income ETF vs Viatris Inc — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.88, while Viatris Inc trades at $16.24 (market cap $18.69B). The key difference: Viatris Inc pays a 2.95% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Viatris Inc is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.
| FEPI | VTRS | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $49.54 | $17.86 |
52-Week Low | $37.98 | $9.49 |
Market Cap | — | $18.69B |
Enterprise Value | — | $30.80B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FEPI trades at $41.88 with minimal daily movement, showing technical bullish signals from moving averages while oscillators remain neutral. The ETF generates substantial income through weekly dividend distributions averaging $0.20-0.21 per share, funded by its covered call strategy on concentrated AI and tech holdings. Recent news highlights the fund's transition to weekly distributions and ongoing discussions about its aggressive income approach.
The high-yield strategy presents income opportunities but carries significant risk from NAV erosion during market downturns. While technical indicators suggest near-term strength, fundamental concerns about the sustainability of 25% yields and concentrated exposure to volatile tech names warrant cautious positioning. The covered call approach limits upside potential while providing consistent cash flow.
Viatris (VTRS) trades at $16.33, up 0.31% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q2 2026 EPS of $0.69, exceeding expectations, and revenue growth of 5% year-over-year. However, negative net income margins and a high P/E ratio of 236.2 highlight profitability challenges. Recent developments include FDA approval for Gwyn Lo contraceptive patch and ongoing divestitures to sharpen focus.
Outlook remains mixed: operational improvements and dividend payments offer stability, but persistent net losses and high debt pose risks. Analyst consensus leans Hold (61.54%), reflecting cautious optimism amid execution uncertainties. Investment appeal hinges on successful margin recovery and debt management in a competitive generic drug market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Rex Fang & Innovation Equity Premium Income ETF
FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.
Read more on FEPI →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
